Arcutis Biotherapeutics (NASDAQ:ARQT) Upgraded by Mizuho to Buy
Mizuho upgraded shares of Arcutis Biotherapeutics (NASDAQ:ARQT – Free Report) from a neutral rating to a buy rating in a research report report published on Tuesday morning, Marketbeat.com reports. The firm currently has $8.00 price objective on the stock, up from their prior price objective of $4.00. Several other research firms have also recently issued […]
More Stories
ChampionX Q3 EPS Estimate Reduced by Capital One Financial
ChampionX Co. (NASDAQ:CHX – Free Report) – Research analysts at Capital One Financial decreased their Q3 2024 EPS estimates for...
Stifel Canada Comments on Kinross Gold Q3 Earnings
Kinross Gold Co. (NYSE:KGC – Free Report) (TSE:K) – Investment analysts at Stifel Canada issued their Q3 2024 earnings estimates...
What is Stifel Canada’s Estimate for TSE:OR Q3 Earnings?
Osisko Gold Royalties Ltd (TSE:OR – Free Report) – Stock analysts at Stifel Canada issued their Q3 2024 earnings per...
Q3 Earnings Forecast for TSE:AEM Issued By Stifel Canada
Agnico Eagle Mines Limited (TSE:AEM – Free Report) (NYSE:AEM) – Research analysts at Stifel Canada issued their Q3 2024 EPS...
Stifel Canada Estimates Calibre Mining Q3 Earnings
Calibre Mining Corp. (TSE:CXB – Free Report) – Equities researchers at Stifel Canada issued their Q3 2024 earnings per share...
Demant A/S (OTCMKTS:WILYY) Upgraded by The Goldman Sachs Group to “Strong-Buy”
Demant A/S (OTCMKTS:WILYY – Get Free Report) was upgraded by stock analysts at The Goldman Sachs Group to a “strong-buy”...